<DOC>
	<DOC>NCT01071915</DOC>
	<brief_summary>This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.</brief_summary>
	<brief_title>Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has given written informed consent before any trialrelated activity is performed. Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages) (except for neoadjuvant hormonal therapy/ includes patients with rising PSA after prostatectomy or radiotherapy) Is a male patient aged 18 years or older Has a screening serum testosterone level &gt;1.5 ng/mL Has an ECOG (Eastern Cooperative Oncology Group) score of ≤ 2 Has a screening PSA value of ≥2 ng/mL Has a life expectancy of at least 12 months Has had previous or is currently under hormonal management of prostate cancer. However, prostatectomy or radiotherapy with curative intention, neoadjuvant/adjuvant hormonal therapy are accepted for a maximum duration of 6 months, at least 6 months prior to Screening Visit Is currently treated with a 5αreductase inhibitor Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy Has a history of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema Has hypersensitivity towards any component of the investigational medicinal product A marked baseline prolongation of QT/QTcF interval A history of additional risk factors for Torsade de Pointes ventricular arrhythmias Has had cancer within the last five years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin Has a known or suspect hepatic, symptomatic biliary disease Has elevated serum ALT level more than the upper limit of normal or serum total bilirubin level above the upper level of normal range at the Screening Visit and confirmed with a second measurement within 21 days Has other clinically significant laboratory abnormalities Has a clinically significant disorder (other than prostate cancer) or any other condition, including alcohol or drug abuse Has a mental incapacity or language barriers precluding adequate understanding or co operation Has received an investigational drug within the last 28 days preceding Screening Visit or longer if considered to possibly influence the outcome of the current trial Has previously participated in any degarelix trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>